As a result, this work aimed to explore whether glutamine intake restriction could affect the sensitivity of NSCLC cells to Almonertinib, which can not only provide the theoretical basis to delay post-marketing drug resistance, but provide a sensitization strategy for possible decreased sensitivity of long-term clinical application of third-generation EGFR small molecule inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.